ISMPP Highlights
ISMPP Members Offered Discount on EMWA Membership
The European Medical Writers Association (EMWA) is offering ISMPP members a 10% discount on EMWA membership. EMWA represents, supports, and trains medical communication professionals. It has more than 1,000 members in Europe and beyond. Members work in all sectors of medical writing…
Record-Setting Attendance at 2017 European Meeting of ISMPP
With 254 attendees participating in the European Meeting of ISMPP, January 17-18, 2017, in London, UK, the Society achieved a record-setting attendance for this increasingly popular conference. Building on its theme, The Evolving Role of Publication Professionals in a Multi-Stakeholder Environment, the meeting focused on…
Global Transparency Committee
With the evolving requirements and expectations for the pharmaceutical industry to increase its transparency related to clinical trial data, medical publication practices and financial disclosure, the need exists for ISMPP members to stay apprised of recent developments and current best practices for adoption by their companies. The ISMPP Global Transparency Committee…
Message from Our Leadership
Robert J. Matheis
ISMPP President and CEO
News and Trends
Clinical Trials: An Overview of the Bread and Butter of Publications
The first reference to a clinical trial can be found in the Bible. In that trial, conducted by King Nebuchadnezzar II (605-562 BC), children fed a strict diet of meat and wine were compared to children fed pulses (eg, beans, peas, lentils) and followed for 3 years (by the way, the children on the meat and wine diet were deemed healthier)…
RWE: A Brave New World for the Medical Publications Professional
Real-World Evidence (RWE), according to the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), comprises “Data used for decision-making that are not collected in conventional randomized controlled trials (RCTs).” RWE is not new; collection of RWE has been mandated for the pharmaceutical industry for many years…
Meta-analysis and Mixed Treatment Comparison Analysis – Powerful Tools with Benefits and Challenges
Evidence-based healthcare decision making is gaining global acceptance in both healthcare policy and clinical practice. Randomized controlled trials (RCTs) are the “gold standard” of evidence, but these studies are usually limited to comparison of two treatments, and thus cannot represent the entirety of treatment options or patient populations…
What Would You Do?
In our role as medical publication professionals, we may occasionally encounter situations in which it is not obvious how to ensure good publication practice. Have you ever wished you could consult the ISMPP membership for guidance when these situations arise? Here’s your opportunity!
What Would You Do? is a section of The MAP that presents case scenarios as an educational tool for medical publication professionals. The section provides a case scenario to ponder, and readers are invited to participate in a poll by selecting one of the listed solutions. Readers can also submit their thoughts on the scenario anonymously. The poll results, plus educational insights, are posted in a later issue for readers to digest.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
ISMPP (pronounced IzMap) is the only nonprofit organization founded by medical publication professionals for medical publication professionals